

11th March, 2015

BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

Dear Sirs,

This has reference to your email dated March 11, 2015 regarding the news item appearing in The Financial Express newspaper titled, "Cipla's gain in German firm's drug patent loss".

We wish to clarify that, in February 2013, Company had filed a post grant opposition before the patent office against grant of patent for the crystalline form of the molecule Tiotropium bromide monohydrate. The patent office, in its recent ruling, has revoked grant of the aforesaid patent.

The Company continues to put patient access first as an important priority. Company has been marketing the generic version of Tiotropium bromide monohydrate under the brand name 'Tiova' since the year 2003. Following the launch of Tiova, Company has also introduced two more combination drugs i.e. 'Tiotropium + Formoterol' under the brand name 'Duova' and 'Tiotropium + Formoterol + Ciclesonide' under the brand name 'Triohale'.

The above development is in the ordinary course of business. The Company has over 1500 products in its portfolio which generate annual revenues in excess of Rs. 10,000 crore and hence the revenues/profits from the sale of aforesaid products is not expected to be material in the current financial year.

Thank you,

Yours faithfully,
For Cipla Limited



Mital Sanghvi
Company Secretary